Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Samantha Ruth Prabhu shares valuable insights on the importance of mental and physical health in relationships following her ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Frampton announced 10 spring concerts in January. He'd briefly considered farewell dates following his 2019 diagnosis with inclusion body myositis, a degenerative disease of the muscles. Frampton's ...

State Theatre New Jersey will present Rock & Roll Hall of Fame inductee and Grammy Award-winning guitarist, Peter Frampton – ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...